Johansson Ida, Ringnér Markus, Hedenfalk Ingrid
Division of Oncology, Department of Clinical Sciences, Lund and CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden.
PLoS One. 2013 Oct 23;8(10):e78299. doi: 10.1371/journal.pone.0078299. eCollection 2013.
The rapidly growing collection of diverse genome-scale data from multiple tumor types sheds light on various aspects of the underlying tumor biology. With the objective to identify genes of importance for breast tumorigenesis in men and to enable comparisons with genes important for breast cancer development in women, we applied the computational framework COpy Number and EXpression In Cancer (CONEXIC) to detect candidate driver genes among all altered passenger genes. Unique to this approach is that each driver gene is associated with several gene modules that are believed to be altered by the driver. Thirty candidate drivers were found in the male breast cancers and 67 in the female breast cancers. We identified many known drivers of breast cancer and other types of cancer, in the female dataset (e.g. GATA3, CCNE1, GRB7, CDK4). In contrast, only three known cancer genes were found among male breast cancers; MAP2K4, LHP, and ZNF217. Many of the candidate drivers identified are known to be involved in processes associated with tumorigenesis, including proliferation, invasion and differentiation. One of the modules identified in male breast cancer was regulated by THY1, a gene involved in invasion and related to epithelial-mesenchymal transition. Furthermore, men with THY1 positive breast cancers had significantly inferior survival. THY1 may thus be a promising novel prognostic marker for male breast cancer. Another module identified among male breast cancers, regulated by SPAG5, was closely associated with proliferation. Our data indicate that male and female breast cancers display highly different landscapes of candidate driver genes, as only a few genes were found in common between the two. Consequently, the pathobiology of male breast cancer may differ from that of female breast cancer and can be associated with differences in prognosis; men diagnosed with breast cancer may consequently require different management and treatment strategies than women.
来自多种肿瘤类型的、快速增长的各种基因组规模数据,揭示了潜在肿瘤生物学的各个方面。为了确定对男性乳腺肿瘤发生重要的基因,并能够与对女性乳腺癌发展重要的基因进行比较,我们应用了癌症中的拷贝数与表达计算框架(CONEXIC),以在所有改变的乘客基因中检测候选驱动基因。这种方法的独特之处在于,每个驱动基因都与几个据信会被该驱动基因改变的基因模块相关联。在男性乳腺癌中发现了30个候选驱动基因,在女性乳腺癌中发现了67个。我们在女性数据集中鉴定出了许多已知的乳腺癌和其他类型癌症的驱动基因(例如GATA3、CCNE1、GRB7、CDK4)。相比之下,在男性乳腺癌中仅发现了三个已知的癌症基因;MAP2K4、LHP和ZNF217。所鉴定出的许多候选驱动基因已知参与与肿瘤发生相关的过程,包括增殖、侵袭和分化。在男性乳腺癌中鉴定出的一个模块受THY1调控,THY1是一个参与侵袭且与上皮-间质转化相关的基因。此外,THY1阳性乳腺癌男性的生存率明显较低。因此,THY1可能是男性乳腺癌一个有前景的新型预后标志物。在男性乳腺癌中鉴定出的另一个受SPAG5调控的模块与增殖密切相关。我们的数据表明,男性和女性乳腺癌显示出高度不同的候选驱动基因格局,因为两者之间仅发现了少数共同基因。因此,男性乳腺癌的病理生物学可能与女性乳腺癌不同,并且可能与预后差异相关;因此,被诊断患有乳腺癌的男性可能需要与女性不同的管理和治疗策略。